SGD Pharma Sustainability Report Details Global Efforts
SGD Pharma has published its 2022 Corporate Social Responsibility Report to underscore its commitment to a green and sustainable present and future. The document is published soon after the company received ECOVADIS Gold award, achieving its highest ever score of 75 out of 100.
Key achievements reported include: 100% of all SGD Pharma owned glass manufacturing plants are ISO 45001 certified; 100% of SGD Pharma sites are certified with ISO 14001; 100% of critical suppliers have CSR clauses in their contracts; an average 26 hours of training per employee; and >20% reduction in water consumption versus 2020.
The company-wide focus on CSR under CEO Olivier Rousseau and with new investors PAI Partners on board means stretch targets have been set already: a 35% reduction in carbon footprint by 2030; 65% reduction in carbon footprint by 2040 (compared with 2020 baseline); zero accidents; and SA 8000 certification of the plant in India.
As a leader in manufacturing of pharmaceutical-grade glass, SGD Pharma takes its global and local responsibilities seriously. Each location has an energized CSR plan deployed locally and conforms to the company’s overall standards.
The company has made significant investment in its global plants and infrastructure as part of a continual search for improvements in energy consumption. This includes furnace renovations and updated glass production facilities in all five plants, including furnace 2 in Sucy-en-Brie, France and Saint-Quentin-La-Motte, France, which has both a full electrical furnace and a second oxy-fuel combustion furnace equipped with electrical boosting, both of which allow the plant to produce glass with low carbon emissions. SGD Pharma has also committed to uplift its decarbonization investment by 20% over the coming 15 years.
